Display options
Cite
Moiseev RV, Morrison PWJ, Steele F, et al. Penetration Enhancers in Ocular Drug Delivery. Pharmaceutics. 2019;11(7)doi: 10.3390/pharmaceutics11070321.
Moiseev, R. V., Morrison, P. W. J., Steele, F., & Khutoryanskiy, V. V. (2019). Penetration Enhancers in Ocular Drug Delivery. Pharmaceutics, 11(7), . https://doi.org/10.3390/pharmaceutics11070321
Moiseev, Roman V, et al. "Penetration Enhancers in Ocular Drug Delivery." Pharmaceutics vol. 11,7 (2019). doi: https://doi.org/10.3390/pharmaceutics11070321
Moiseev RV, Morrison PWJ, Steele F, Khutoryanskiy VV. Penetration Enhancers in Ocular Drug Delivery. Pharmaceutics. 2019 Jul 09;11(7). doi: 10.3390/pharmaceutics11070321. PMID: 31324063; PMCID: PMC6681039.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2019 Jul 09;11(7). doi: 10.3390/pharmaceutics11070321.

Penetration Enhancers in Ocular Drug Delivery.

Pharmaceutics

Roman V Moiseev, Peter W J Morrison, Fraser Steele, Vitaliy V Khutoryanskiy

Affiliations

  1. Reading School of Pharmacy, University of Reading, Whiteknights, P.O. Box 224, Reading RG66AD, UK.
  2. MC2 Therapeutics, James House, Emlyn Lane, Leatherhead KT22 7EP, UK.
  3. Reading School of Pharmacy, University of Reading, Whiteknights, P.O. Box 224, Reading RG66AD, UK. [email protected].

PMID: 31324063 PMCID: PMC6681039 DOI: 10.3390/pharmaceutics11070321

Abstract

There are more than 100 recognized disorders of the eye. This makes the development of advanced ocular formulations an important topic in pharmaceutical science. One of the ways to improve drug delivery to the eye is the use of penetration enhancers. These are defined as compounds capable of enhancing drug permeability across ocular membranes. This review paper provides an overview of anatomical and physiological features of the eye and discusses some common ophthalmological conditions and permeability of ocular membranes. The review also presents the analysis of literature on the use of penetration-enhancing compounds (cyclodextrins, chelating agents, crown ethers, bile acids and bile salts, cell-penetrating peptides, and other amphiphilic compounds) in ocular drug delivery, describing their properties and modes of action.

Keywords: cornea; ocular conditions; ocular drug delivery; ophthalmology; penetration enhancers

References

  1. J Pharm Sci. 1998 Dec;87(12):1479-88 - PubMed
  2. Adv Drug Deliv Rev. 1999 Mar 1;36(1):59-79 - PubMed
  3. Biol Pharm Bull. 2000 Dec;23(12):1524-7 - PubMed
  4. Toxicol Lett. 2001 May 31;122(1):1-8 - PubMed
  5. Acta Ophthalmol (Copenh). 1975 Jun;53(3):348-57 - PubMed
  6. Pharm Res. 2001 Nov;18(11):1497-508 - PubMed
  7. Acta Ophthalmol Scand. 2002 Apr;80(2):144-50 - PubMed
  8. Br J Ophthalmol. 1975 Nov;59(11):667-9 - PubMed
  9. Drug Dev Ind Pharm. 2002 Apr;28(4):353-69 - PubMed
  10. J Ocul Pharmacol Ther. 2002 Oct;18(5):419-27 - PubMed
  11. Annu Rev Biochem. 2003;72:137-74 - PubMed
  12. Drug Dev Ind Pharm. 2003 Feb;29(2):223-30 - PubMed
  13. Pharmazie. 2003 Jul;58(7):497-501 - PubMed
  14. Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5095-101 - PubMed
  15. Cornea. 2004 Nov;23(8):804-11 - PubMed
  16. J Zhejiang Univ Sci B. 2005 Jan;6(1):69-73 - PubMed
  17. Int J Pharm. 2005 Feb 16;290(1-2):83-9 - PubMed
  18. Clin Chim Acta. 2006 Feb;364(1-2):321-7 - PubMed
  19. J Pharm Pharmacol. 2006 Jan;58(1):45-50 - PubMed
  20. Biol Pharm Bull. 2006 Jan;29(1):155-60 - PubMed
  21. Curr Drug Deliv. 2006 Apr;3(2):207-17 - PubMed
  22. Mol Vis. 2006 Apr 26;12:415-21 - PubMed
  23. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26 - PubMed
  24. Prog Retin Eye Res. 2007 Jan;26(1):78-98 - PubMed
  25. J Med Chem. 2007 Mar 8;50(5):1007-18 - PubMed
  26. Colloids Surf B Biointerfaces. 2007 Aug 1;58(2):197-202 - PubMed
  27. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4038-43 - PubMed
  28. Eur J Pharm Biopharm. 2008 Mar;68(3):467-78 - PubMed
  29. Front Biosci. 2008 Jan 01;13:3136-49 - PubMed
  30. Drug Discov Today. 2008 Feb;13(3-4):135-43 - PubMed
  31. Drug Discov Today. 2008 Feb;13(3-4):144-51 - PubMed
  32. ChemMedChem. 2008 Oct;3(10):1478-92 - PubMed
  33. Curr Eye Res. 2008 Aug;33(8):661-7 - PubMed
  34. Adv Drug Deliv Rev. 2008 Dec 14;60(15):1663-73 - PubMed
  35. Pharm Res. 2009 Feb;26(2):395-403 - PubMed
  36. Biochim Biophys Acta. 2009 Apr;1788(4):892-910 - PubMed
  37. Ophthalmologica. 2009;223(2):136-8 - PubMed
  38. J Ocul Pharmacol Ther. 2009 Apr;25(2):113-9 - PubMed
  39. J Lipid Res. 2009 Oct;50(10):1955-66 - PubMed
  40. Talanta. 2009 Jun 15;78(4-5):1484-8 - PubMed
  41. Drug Deliv. 2009 May;16(4):224-9 - PubMed
  42. J Pharm Sci. 2010 Jan;99(1):119-27 - PubMed
  43. J Int Med Res. 2009 May-Jun;37(3):791-802 - PubMed
  44. Drug Deliv. 2009 Oct;16(7):399-404 - PubMed
  45. J Ocul Pharmacol. 1990 Winter;6(4):329-36 - PubMed
  46. Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3162-70 - PubMed
  47. Methods Mol Biol. 2011;683:21-9 - PubMed
  48. Open Ophthalmol J. 2010 Sep 03;4:52-9 - PubMed
  49. Invest Ophthalmol Vis Sci. 2011 Jun 01;52(6):3548-56 - PubMed
  50. J Pharm Sci. 2011 Aug;100(8):3186-3195 - PubMed
  51. J Pharm Bioallied Sci. 2011 Jan;3(1):89-100 - PubMed
  52. Eur J Pharm Sci. 2012 Aug 30;47(1):131-8 - PubMed
  53. Drug Dev Ind Pharm. 2013 May;39(5):791-8 - PubMed
  54. Int J Pharm. 2013 Jan 20;440(2):148-53 - PubMed
  55. Mol Pharm. 2013 Feb 4;10(2):756-62 - PubMed
  56. Int J Pharm. 2013 Apr 15;447(1-2):12-21 - PubMed
  57. Int J Nanomedicine. 2013;8:1921-33 - PubMed
  58. Ophthalmology. 2013 Sep;120(9):1778-85 - PubMed
  59. Invest Ophthalmol Vis Sci. 2013 Dec 13;54(14):ORSF54-9 - PubMed
  60. J Pharm Pharmacol. 1987 Feb;39(2):124-6 - PubMed
  61. Mol Pharm. 2014 Apr 7;11(4):1218-27 - PubMed
  62. Small. 2014 Apr 24;10(8):1575-84 - PubMed
  63. Int J Pharm. 2014 Sep 10;472(1-2):56-64 - PubMed
  64. Ophthalmology. 2014 Nov;121(11):2081-90 - PubMed
  65. Ther Deliv. 2014 Dec;5(12):1297-315 - PubMed
  66. Nature. 2015 Jul 30;523(7562):607-11 - PubMed
  67. Drug Deliv Transl Res. 2016 Dec;6(6):634-647 - PubMed
  68. Int J Pharm. 2016 Mar 30;501(1-2):1-9 - PubMed
  69. Eur J Pharm Biopharm. 2016 Oct;107:171-9 - PubMed
  70. Expert Opin Drug Deliv. 2017 May;14(5):631-645 - PubMed
  71. Mol Pharm. 2016 Nov 7;13(11):3876-3883 - PubMed
  72. Int J Pharm. 2017 Oct 15;531(2):413-423 - PubMed
  73. Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2578-2590 - PubMed
  74. Int J Pharm. 2017 Aug 30;529(1-2):168-177 - PubMed
  75. JCI Insight. 2017 Jul 20;2(14):null - PubMed
  76. Mol Pharm. 2017 Oct 2;14(10):3528-3538 - PubMed
  77. J Pharmacobiodyn. 1988 Feb;11(2):115-20 - PubMed
  78. J Pharmacobiodyn. 1988 May;11(5):330-4 - PubMed
  79. Methods Mol Biol. 2018;1695:1-10 - PubMed
  80. Int J Pharm. 2018 Mar 1;538(1-2):119-129 - PubMed
  81. Drug Deliv Transl Res. 2018 Jun;8(3):461-472 - PubMed
  82. J Control Release. 2018 Aug 28;284:84-102 - PubMed
  83. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2880-2898 - PubMed
  84. Biomed Pharmacother. 2018 Nov;107:1564-1582 - PubMed
  85. Invest Ophthalmol Vis Sci. 1985 Jan;26(1):110-3 - PubMed
  86. Exp Eye Res. 1971 Jan;11(1):43-8 - PubMed
  87. Arch Ophthalmol. 1968 Jul;80(1):3-20 - PubMed
  88. Br J Ophthalmol. 1982 Nov;66(11):705-8 - PubMed
  89. Pharm Res. 1995 Aug;12(8):1146-50 - PubMed
  90. J Pharm Sci. 1994 Jan;83(1):85-90 - PubMed
  91. Pharm Res. 1997 May;14(5):556-67 - PubMed

Publication Types